Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer-Reference-Cited by-同舟云学术

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer

Published:2021-12 Issue:3 Volume:163 Page:465-472
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Konecny G.E.,Hendrickson A.E. Wahner,Davidson T.M.,Winterhoff B.J.,Ma S.,Mahner S.,Sehouli J.,Fasching P.A.,Feisel-Schwickardi G.,Poelcher M.,Roman L.D.,Rody A.,Karlan B.Y.,Mullany S.A.,Chen H.,Ray-Coquard I.L.,Provencher D.M.,Yachnin A.,Cottu P.H.,Glaspy J.A.,Haluska P.,Slamon D.J.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference48 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J. Clin.,2020

2. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer;Colombo;Crit. Rev. Oncol. Hematol.,2014

3. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer;Ray-Coquard;N. Engl. J. Med.,2019

4. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas;Ouban;Hum. Pathol.,2003

5. The dichotomy of the insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?;Crudden;Growth Hormon. IGF Res.,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma;Clinical Cancer Research;2023-07-03

2. GH and IGF1 in cancer therapy resistance;Endocrine-Related Cancer;2023-06-07

3. Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer;Gynecologic Oncology;2023-03

4. Insulin-like growth factor-1 signaling in the tumor microenvironment: Carcinogenesis, cancer drug resistance, and therapeutic potential;Frontiers in Endocrinology;2022-08-09

5. Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT;Pharmaceutics;2022-07-15